Company: BIVIW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001520138-25-000247
Chunk: 56

Company: BIOVIE INC.
Filing Date: 2025-08-08
Form: 424B5
Chunk 56
---
ained in secrecy until patents are issued. The publication of discoveries in the scientific or patent literature frequently occurs
substantially later than the date on which the underlying discoveries were made and patent applications were filed. Because patents can
take many years to issue, there may be currently pending applications of which we are unaware that may later result in issued patents
that our products or product candidates infringe. For example, pending applications may exist that provide support or can be amended to
provide support for a claim that results in an issued patent that our product infringes.

Even if we believe third-party intellectual property
claims are without merit, there is no assurance that a court would find in our favor on questions of claim scope, infringement, validity,
enforceability or priority. A court of competent jurisdiction could hold that third-party patents asserted against us are valid, enforceable
and infringed, which could materially and adversely affect our ability to commercialize any drug candidates we may develop and any other
drug candidates or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such
U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present
clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction
would invalidate the claims of any such U.S. patent.

If we are found to infringe, misappropriate or
otherwise violate a third party’s intellectual property rights, and we are unsuccessful in demonstrating that such rights are invalid
or unenforceable, we could be required to obtain a license from such a third party in order to continue developing and marketing our products
and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were
able to obtain a license, it could be or may become non-exclusive, thereby giving our competitors access to the same technologies licensed
to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. A finding of infringement
could prevent us from commercializing our drug candidates or force us to cease some of our business operations. In the event of a successful
claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful
infringement, pay royalties and other fees, redesign our infringing drug candidate or obtain one